| abstract |
The present invention relates to pyrazoloquinazolinones and pyrroloquinazolinone derivatives of general formula (I), and pharmaceutical compositions containing them, as well as conditions associated with glutamatergic signaling and / or functional changes in mammals and / or With respect to their use in the treatment and / or prevention of conditions that may be affected by changes in glutamate levels or signaling, in particular their use in the treatment and / or prevention of acute and chronic neurological and / or psychiatric disorders . |